Biotech Startups

Vedana Therapeutics develops next-generation biologic medicines for migraine prevention, targeting PACAP and CGRP-independent pathways to address unmet needs in patients inadequately controlled by current therapies. The company focuses on the neurological and pharmaceutical sectors to serve the global migraine patient population.

2 investors

Vedere Bio develops optogenetics-based gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA), using proprietary AAV vectors for intravitreal administration to restore vision in visually impaired patients globally.

2 investors

Vega BioImaging develops a cancer diagnostic platform combining nanobead technology, optical imaging, and AI-powered analysis to enable quantitative detection of multiple cancer biomarkers simultaneously in tissue biopsies. The solution improves upon traditional immunohistochemistry methods for pathology laboratories and clinical research settings.

2 investors

Biotechnology company developing products for overactive bladder and irritable bowel syndrome.

2 investors

Velocity Bio is developing a biophysical assay platform designed to generate larger-scale, higher-quality data for early-stage drug discovery. The platform aims to shift early discovery from blind screening toward targeted molecular design.

2 investors

Velocity operates dedicated and embedded clinical research sites across the United States, providing the staff, equipment, study contracting, regulatory documentation, and business development support needed to run clinical trials. It partners with physician groups, independent practices, and health centers to add research capabilities and covers a wide range of therapeutic areas.

2 investors

Vensica is a clinical-stage medical company developing ViXe, a needle-free treatment for overactive bladder that combines the neurotoxin Xeomin with Vibe, an ultrasound-based drug delivery device that microinjects medication into the bladder wall. The company focuses on urology therapeutics for unmet medical needs.

2 investors

Ventuno is a biotech company developing cancer therapies that leverage the immune system to target and eliminate cancer cells in difficult-to-treat tumors. The company focuses on immunotherapy approaches to advance cancer care.

2 investors

Veracyte develops genomic diagnostic tests for cancer, offering laboratory developed tests for thyroid, prostate, bladder, and breast cancers performed in its CLIA-certified, high-complexity labs. Its tests analyze each patient's tumor biology to help clinicians make personalized treatment decisions.

2 investors

Verdesian Life Sciences is a leading agrochemical platform focused on biological and nutritional fertilizer enhancers, seed treatments, and inoculants for specialty crops. The company serves farmers and the agricultural industry.

2 investors

Vergent develops tumor-targeted fluorescent imaging agents designed to enhance surgeons' ability to visualize tumors during minimally invasive and robotic-assisted cancer surgery. The company's lead program, abenacianine for injection, is in Phase 2b clinical evaluation for lung cancer surgery applications.

2 investors

Verigraft develops personalized tissue-engineered products for severe diseases, including vascular grafts, nerve grafts, and heart valves, targeting regenerative medicine markets globally. The company's proprietary technology creates biological solutions for conditions such as chronic venous insufficiency, peripheral arterial disease, and heart valve disease.

2 investors

Verinnogen develops data collection technology for pre-clinical cancer research, aiming to improve the accuracy, repeatability, and reliability of research data. The company draws on expertise in cancer biology and medical device development.

2 investors

Verinomics develops crop improvement technology by combining genomics, computational biology, and a transgene-free gene editing platform, with an AI-driven population genomics tool to identify high-value trait genes. It serves breeding programs, agricultural businesses, and research institutions focused on specialty and vegetatively propagated crops such as leafy greens.

2 investors

Veriskin makes a handheld, AI-powered medical device that assesses suspect skin growths by imaging cutaneous blood flow in real time, delivering results in about two minutes. It is aimed at clinical skin cancer screening, supporting early detection while reducing false positives and referrals.

2 investors

Verley Food addresses the global dairy protein deficit by promoting a diversified protein mix that combines conventional farming, precision fermentation proteins, and plant-based products. The company focuses on sustainable protein production solutions to meet rising global demand while ensuring food sovereignty and reducing environmental impact.

2 investors

VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings. The company focuses on designing and commercializing innovative medical devices to address unmet clinical needs.

2 investors

Verogen provides NGS sequencing systems and reagent solutions for forensic and research laboratories, with offerings including the MiSeq FGx Sequencing System and flexible financing options like leasing, reagent rental programs, and bundled workflows.

2 investors

Verrica Pharmaceuticals is a therapeutics company developing and commercializing treatments for dermatological diseases, including molluscum contagiosum, common warts, and skin cancers such as basal cell and squamous cell carcinoma. Its products serve dermatology prescribers, payers, and patients, with a lead drug-device combination based on topical cantharidin.

2 investors

Versant Ventures is a venture capital firm that invests in deep technology and life sciences companies.

2 investors

GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with a focus on acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma, urea cycle disorders, and organic acidemias. Its pipeline spans eight R&D programs plus a diagnostic franchise for NASH/MASH and ammonia, and it discovered elafibranor, now approved and marketed as Iqirvo for primary biliary cholangitis.

2 investors

Vertosa develops water-dispersible emulsion technology and active ingredients that infused product makers, such as beverage and edibles producers, use to formulate stable, homogeneous, and bioavailable products. It provides customized aqueous solutions sold in bulk as dosed active ingredients along with formulation and manufacturing support.

2 investors

VIA produces 3-Methylanisole (3-MA), a synthetic aromatic biofuel, through proprietary engineered yeast fermentation that converts starch, sugar, and cellulosic sugars into the aromatic compound. The company serves fuel manufacturers and chemical producers seeking scalable bio-based alternatives to petroleum-derived aromatics.

2 investors

Vial develops first- and best-in-class biologics — including RNA, antibody, and small molecule programs — using AI-driven target discovery, molecule design, and high-throughput experimental validation, focused on immunology and inflammatory disorders. It also runs programs through its own clinical trial platform for automated clinical trials.

2 investors